TRAVERE THERAPEUTICS, INC. Share-based Payment Arrangement, Expense
TRAVERE THERAPEUTICS, INC. (TVTX) reported Share-based Payment Arrangement, Expense of $21.79 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-04
- TRAVERE THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $21.79M, a 104.60% increase year-over-year.
- TRAVERE THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $16.15M, a 40.50% increase year-over-year.
- TRAVERE THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $11.46M, a 24.41% increase year-over-year.
- TRAVERE THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $11.26M, a 40.42% increase year-over-year.
- TRAVERE THERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2025 was $44.87M, a 21.55% increase from fiscal 2024.
- TRAVERE THERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2024 was $36.91M, a 16.57% decline from fiscal 2023.
- TRAVERE THERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2023 was $44.25M, a 16.00% increase from fiscal 2022.
- TRAVERE THERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2022 was $38.14M, a 29.01% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 3 month as first filed | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 6 month as first filed | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 9 month as first filed | Share-based Payment Arrangement, Expense 12 month | Share-based Payment Arrangement, Expense 12 month as first filed | Share-based Payment Arrangement, Expense 31 month | Share-based Payment Arrangement, Expense 34 month |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $21.79M 10-Q · filed 2026-08-04 | $37.93M 10-Q · filed 2026-08-04 | $49.40M derived: sum of 3 quarters · filed 2026-08-04 | $60.66M derived: sum of 4 quarters · filed 2026-08-04 | ||||||
| 2026-03-31 | $16.15M 10-Q · filed 2026-05-04 | $27.61M derived: sum of 2 quarters · filed 2026-05-04 | $38.87M derived: sum of 3 quarters · filed 2026-05-04 | $49.52M derived: sum of 4 quarters · filed 2026-08-04 | ||||||
| 2025-12-31 | $11.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $22.73M derived: sum of 2 quarters · filed 2026-02-19 | $33.38M derived: sum of 3 quarters · filed 2026-08-04 | $44.87M 10-K · filed 2026-02-19 | ||||||
| 2025-09-30 | $11.26M 10-Q · filed 2025-10-30 | $21.91M derived: sum of 2 quarters · filed 2026-08-04 | $33.40M 10-Q · filed 2025-10-30 | $42.62M derived: sum of 4 quarters · filed 2026-08-04 | ||||||
| 2025-06-30 | $10.65M 10-Q · filed 2026-08-04 | $22.14M 10-Q · filed 2026-08-04 | $31.36M derived: sum of 3 quarters · filed 2026-08-04 | $39.38M derived: sum of 4 quarters · filed 2026-08-04 | ||||||
| 2025-03-31 | $11.49M 10-Q · filed 2026-05-04 | $20.71M derived: sum of 2 quarters · filed 2026-05-04 | $28.73M derived: sum of 3 quarters · filed 2026-05-04 | $38.65M derived: sum of 4 quarters · filed 2026-05-04 | ||||||
| 2024-12-31 | $9.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $17.24M derived: sum of 2 quarters · filed 2026-02-19 | $27.16M derived: sum of 3 quarters · filed 2026-02-19 | $36.91M 10-K · filed 2026-02-19 | ||||||
| 2024-09-30 | $8.02M 10-Q · filed 2025-10-30 | $17.94M derived: sum of 2 quarters · filed 2025-10-30 | $27.70M 10-Q · filed 2025-10-30 | $35.84M derived: sum of 4 quarters · filed 2026-02-19 | ||||||
| 2024-06-30 | $9.92M 10-Q · filed 2025-08-06 | $19.68M 10-Q · filed 2025-08-06 | $27.82M derived: sum of 3 quarters · filed 2026-02-19 | $39.14M derived: sum of 4 quarters · filed 2026-02-19 | ||||||
| 2024-03-31 | $9.76M 10-Q · filed 2025-05-01 | $17.90M derived: sum of 2 quarters · filed 2026-02-19 | $29.22M derived: sum of 3 quarters · filed 2026-02-19 | $40.53M derived: sum of 4 quarters · filed 2026-02-19 | ||||||
| 2023-12-31 | $8.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $19.46M derived: sum of 2 quarters · filed 2026-02-19 | $30.78M derived: sum of 3 quarters · filed 2026-02-19 | $44.25M 10-K · filed 2026-02-19 | ||||||
| 2023-09-30 | $11.32M 10-Q · filed 2024-10-31 | $22.63M derived: sum of 2 quarters · filed 2024-10-31 | $36.10M 10-Q · filed 2024-10-31 | $45.40M derived: sum of 4 quarters · filed 2025-02-21 | ||||||
| 2023-06-30 | $11.31M 10-Q · filed 2024-08-01 | $11.60M 10-Q · filed 2023-08-03 | $24.78M 10-Q · filed 2024-08-01 | $25.37M 10-Q · filed 2023-08-03 | $34.08M derived: sum of 3 quarters · filed 2025-02-21 | $42.67M derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2023-03-31 | $13.47M 10-Q · filed 2024-05-06 | $13.76M 10-Q · filed 2023-05-04 | $22.77M derived: sum of 2 quarters · filed 2025-02-21 | $31.36M derived: sum of 3 quarters · filed 2025-02-21 | $43.99M derived: sum of 4 quarters · filed 2025-02-21 | |||||
| 2022-12-31 | $9.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $17.89M derived: sum of 2 quarters · filed 2025-02-21 | $30.52M derived: sum of 3 quarters · filed 2025-02-21 | $38.14M 10-K · filed 2025-02-21 | $39.18M 10-K · filed 2023-02-23 | |||||
| 2022-09-30 | $8.59M 10-Q · filed 2023-11-07 | $8.83M 10-Q · filed 2022-10-27 | $21.23M derived: sum of 2 quarters · filed 2023-11-07 | $28.85M 10-Q · filed 2023-11-07 | $29.65M 10-Q · filed 2022-10-27 | $36.79M derived: sum of 4 quarters · filed 2024-02-20 | ||||
| 2022-06-30 | $12.64M 10-Q · filed 2023-08-03 | $20.82M 10-Q · filed 2023-08-03 | $28.20M derived: sum of 3 quarters · filed 2024-02-20 | $35.19M derived: sum of 4 quarters · filed 2024-02-20 | ||||||
| 2022-03-31 | $8.19M 10-Q · filed 2023-05-04 | $15.56M derived: sum of 2 quarters · filed 2024-02-20 | $22.55M derived: sum of 3 quarters · filed 2024-02-20 | $30.06M derived: sum of 4 quarters · filed 2024-02-20 | ||||||
| 2021-12-31 | $7.38M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $14.36M derived: sum of 2 quarters · filed 2024-02-20 | $21.87M derived: sum of 3 quarters · filed 2024-02-20 | $29.57M 10-K · filed 2024-02-20 | $30.77M 10-K · filed 2022-02-24 | |||||
| 2021-09-30 | $6.99M 10-Q · filed 2022-10-27 | $14.50M derived: sum of 2 quarters · filed 2022-10-27 | $22.19M 10-Q · filed 2022-10-27 | $28.54M derived: sum of 4 quarters · filed 2023-02-23 | ||||||
| 2021-06-30 | $7.51M 10-Q · filed 2022-08-04 | $15.20M 10-Q · filed 2022-08-04 | $21.56M derived: sum of 3 quarters · filed 2023-02-23 | $26.95M derived: sum of 4 quarters · filed 2023-02-23 | ||||||
| 2021-03-31 | $7.69M 10-Q · filed 2022-05-05 | $14.05M derived: sum of 2 quarters · filed 2023-02-23 | $19.44M derived: sum of 3 quarters · filed 2023-02-23 | $25.40M derived: sum of 4 quarters · filed 2023-02-23 | ||||||
| 2020-12-31 | $6.35M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $11.75M derived: sum of 2 quarters · filed 2023-02-23 | $17.70M derived: sum of 3 quarters · filed 2023-02-23 | $23.61M 10-K · filed 2023-02-23 | ||||||
| 2020-09-30 | $5.40M 10-Q · filed 2021-10-29 | $11.35M derived: sum of 2 quarters · filed 2021-10-29 | $17.26M 10-Q · filed 2021-10-29 | $21.76M derived: sum of 4 quarters · filed 2022-02-24 | ||||||
| 2020-06-30 | $5.95M 10-Q · filed 2021-07-29 | $11.86M 10-Q · filed 2021-07-29 | $16.36M derived: sum of 3 quarters · filed 2022-02-24 | $20.70M derived: sum of 4 quarters · filed 2022-02-24 | ||||||
| 2020-03-31 | $5.91M 10-Q · filed 2021-05-06 | $10.41M derived: sum of 2 quarters · filed 2022-02-24 | $14.75M derived: sum of 3 quarters · filed 2022-02-24 | $20.50M derived: sum of 4 quarters · filed 2022-02-24 | ||||||
| 2019-12-31 | $4.50M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $8.84M derived: sum of 2 quarters · filed 2022-02-24 | $14.59M derived: sum of 3 quarters · filed 2022-02-24 | $21.11M 10-K · filed 2022-02-24 | ||||||
| 2019-09-30 | $4.34M 10-Q · filed 2020-11-05 | $10.09M derived: sum of 2 quarters · filed 2020-11-05 | $16.61M 10-Q · filed 2020-11-05 | $21.46M derived: sum of 4 quarters · filed 2021-03-01 | ||||||
| 2019-06-30 | $5.75M 10-Q · filed 2020-07-31 | $12.27M 10-Q · filed 2020-07-31 | $17.12M derived: sum of 3 quarters · filed 2021-03-01 | $22.01M derived: sum of 4 quarters · filed 2021-03-01 | ||||||
| 2019-03-31 | $6.52M 10-Q · filed 2020-05-11 | $11.37M derived: sum of 2 quarters · filed 2021-03-01 | $16.26M derived: sum of 3 quarters · filed 2021-03-01 | $21.68M derived: sum of 4 quarters · filed 2021-03-01 | ||||||
| 2018-12-31 | $4.85M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $9.74M derived: sum of 2 quarters · filed 2021-03-01 | $15.16M derived: sum of 3 quarters · filed 2021-03-01 | $19.77M 10-K · filed 2021-03-01 | ||||||
| 2018-09-30 | $4.88M 10-Q · filed 2019-10-30 | $10.31M derived: sum of 2 quarters · filed 2019-10-30 | $14.92M 10-Q · filed 2019-10-30 | $20.50M derived: sum of 4 quarters · filed 2020-02-24 | ||||||
| 2018-06-30 | $5.43M 10-Q · filed 2019-08-06 | $10.04M 10-Q · filed 2019-08-06 | $15.62M derived: sum of 3 quarters · filed 2020-02-24 | $22.58M derived: sum of 4 quarters · filed 2020-02-24 | ||||||
| 2018-03-31 | $4.61M 10-Q · filed 2019-05-07 | $10.19M derived: sum of 2 quarters · filed 2020-02-24 | $17.15M derived: sum of 3 quarters · filed 2020-02-24 | $24.39M derived: sum of 4 quarters · filed 2020-02-24 | ||||||
| 2017-12-31 | $5.58M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24 | $12.54M derived: sum of 2 quarters · filed 2020-02-24 | $19.78M derived: sum of 3 quarters · filed 2020-02-24 | $26.87M 10-K · filed 2020-02-24 | ||||||
| 2017-09-30 | $6.96M 10-Q · filed 2018-11-01 | $14.20M derived: sum of 2 quarters · filed 2018-11-01 | $21.29M 10-Q · filed 2018-11-01 | $28.36M derived: sum of 4 quarters · filed 2019-02-26 | ||||||
| 2017-06-30 | $7.24M 10-Q · filed 2018-08-03 | $14.33M 10-Q · filed 2018-08-03 | $21.40M derived: sum of 3 quarters · filed 2019-02-26 | $29.15M derived: sum of 4 quarters · filed 2019-02-26 | ||||||
| 2017-03-31 | $7.09M 10-Q · filed 2018-07-06 | $14.16M derived: sum of 2 quarters · filed 2019-02-26 | $21.91M derived: sum of 3 quarters · filed 2019-02-26 | $29.40M derived: sum of 4 quarters · filed 2019-02-26 | ||||||
| 2016-12-31 | $7.07M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $14.82M derived: sum of 2 quarters · filed 2019-02-26 | $22.31M derived: sum of 3 quarters · filed 2019-02-26 | $29.10M 10-K · filed 2019-02-26 | ||||||
| 2016-09-30 | $7.75M 10-Q · filed 2017-11-07 | $15.24M derived: sum of 2 quarters · filed 2017-11-07 | $22.03M 10-Q · filed 2017-11-07 | $29.19M derived: sum of 4 quarters · filed 2018-07-06 | ||||||
| 2016-06-30 | $7.49M 10-Q · filed 2017-08-09 | $14.29M 10-Q · filed 2017-08-09 | $21.44M derived: sum of 3 quarters · filed 2018-07-06 | $29.62M derived: sum of 4 quarters · filed 2018-07-06 | ||||||
| 2016-03-31 | $6.79M 10-Q · filed 2017-05-05 | $13.95M derived: sum of 2 quarters · filed 2018-07-06 | $22.13M derived: sum of 3 quarters · filed 2018-07-06 | $27.12M derived: sum of 4 quarters · filed 2018-07-06 | ||||||
| 2015-12-31 | $7.15M derived: 10-K 12 month − 10-Q 9 month · filed 2018-07-06 | $15.33M derived: sum of 2 quarters · filed 2018-07-06 | $20.33M derived: sum of 3 quarters · filed 2018-07-06 | $25.90M 10-K · filed 2018-07-06 | ||||||
| 2015-09-30 | $8.18M 10-Q · filed 2016-11-04 | $13.18M derived: sum of 2 quarters · filed 2016-11-04 | $18.75M 10-Q · filed 2016-11-04 | $25.41M derived: sum of 4 quarters · filed 2017-03-01 | ||||||
| 2015-06-30 | $4.99M 10-Q · filed 2016-08-05 | $10.57M 10-Q · filed 2016-08-05 | $17.23M derived: sum of 3 quarters · filed 2017-03-01 | $20.43M derived: sum of 4 quarters · filed 2017-03-01 | ||||||
| 2015-03-31 | $5.57M 10-Q · filed 2016-05-05 | $5.57M 10-Q · filed 2015-05-11 | $12.24M derived: sum of 2 quarters · filed 2017-03-01 | $15.44M derived: sum of 3 quarters · filed 2017-03-01 | $18.07M derived: sum of 4 quarters · filed 2017-03-01 | |||||
| 2014-12-31 | $6.66M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $9.87M derived: sum of 2 quarters · filed 2017-03-01 | $12.49M derived: sum of 3 quarters · filed 2017-03-01 | $15.90M 10-K · filed 2017-03-01 | ||||||
| 2014-09-30 | $3.20M 10-Q · filed 2015-11-06 | $4.69M 10-Q · filed 2014-11-13 | $5.83M derived: sum of 2 quarters · filed 2015-11-06 | $9.24M 10-Q · filed 2015-11-06 | $14.71M 10-Q · filed 2014-11-13 | $10.12M derived: sum of 4 quarters · filed 2016-02-26 | ||||
| 2014-06-30 | $2.63M 10-Q · filed 2015-08-10 | $6.03M 10-Q · filed 2015-08-10 | $6.91M derived: sum of 3 quarters · filed 2016-02-26 | $8.66M derived: sum of 4 quarters · filed 2016-02-26 | ||||||
| 2014-03-31 | $3.40M 10-Q · filed 2015-05-11 | $4.29M derived: sum of 2 quarters · filed 2016-02-26 | $6.03M derived: sum of 3 quarters · filed 2016-02-26 | |||||||
| 2013-12-31 | $880.50K derived: 10-K 12 month − 10-Q/A 9 month · filed 2016-02-26 | $2.62M derived: sum of 2 quarters · filed 2016-02-26 | $2.91M 10-K · filed 2016-02-26 | $2.91M 10-K · filed 2015-03-11 | $27.30M 10-K/A · filed 2015-07-09 | |||||
| 2013-09-30 | $1.74M 10-Q/A · filed 2015-07-09 | $2.03M 10-Q/A · filed 2015-07-09 | $26.42M 10-Q/A · filed 2015-07-09 | |||||||
| 2012-12-31 | $8.40M derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2015-07-09 | $15.42M derived: sum of 2 quarters · filed 2015-07-09 | $22.41M 10-K/A · filed 2015-07-09 | |||||||
| 2012-09-30 | $7.03M 10-Q/A · filed 2015-07-09 | $14.01M 10-Q/A · filed 2015-07-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |